Diller Gerhard-Paul, Lammers Astrid Elisabeth, Fischer Alicia, Orwat Stefan, Nienhaus Klara, Schmidt Renate, Radke Robert M, De-Torres-Alba Fernando, Kaleschke Gerrit, Marschall Ursula, Bauer Ulrike M, Roth Johannes, Gerß Joachim, Bormann Eike, Baumgartner Helmut
Department of Cardiology III-Adult Congenital and Valvular Heart Disease University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.
Adult Congenital Heart Disease Unit, Royal Brompton Hospital and King's College, Sydney Street, Sw3 6NP London, UK.
Eur Heart J. 2023 Sep 7;44(34):3250-3260. doi: 10.1093/eurheartj/ehad029.
To provide population-based data on the prevalence and clinical significance of immune deficiency syndromes (IDS) associated with congenital heart disease (CHD).
Utilizing administrative German Health System data the prevalence of increased susceptibility to infection (ISI) or confirmed IDS was assessed in CHD patients and compared with an age-matched non-congenital control group. Furthermore, the prognostic significance of IDS was assessed using all-cause mortality and freedom from emergency hospital admission. A total of 54 449 CHD patients were included. Of these 14 998 (27.5%) had ISI and 3034 (5.6%) had a documented IDS (compared with 2.9% of the age-matched general population). During an observation period of 394 289 patient-years, 3824 CHD patients died, and 31 017 patients experienced a combined event of all-cause mortality or emergency admission. On multivariable Cox proportional-hazard analysis, the presence of ISI [hazard ratio (HR): 2.14, P < 0.001] or documented IDS (HR: 1.77, P = 0.035) emerged as independent predictors of all-cause mortality. In addition, ISI and confirmed IDS were associated with a significantly higher risk of emergency hospital admission (P = 0.01 for both on competing risk analysis) during follow-up.
Limited immune competence is common in CHD patients and associated with an increased risk of morbidity and mortality. This highlights the need for structured IDS screening and collaboration with immunology specialists as immunodeficiency may be amenable to specific therapy. Furthermore, studies are required to assess whether IDS patients might benefit from intensified antibiotic shielding or tailored prophylaxis.
提供基于人群的与先天性心脏病(CHD)相关的免疫缺陷综合征(IDS)的患病率及临床意义的数据。
利用德国医疗系统管理数据,评估CHD患者中感染易感性增加(ISI)或确诊IDS的患病率,并与年龄匹配的非先天性对照组进行比较。此外,使用全因死亡率和无急诊入院情况评估IDS的预后意义。共纳入54449例CHD患者。其中14998例(27.5%)有ISI,3034例(5.6%)有记录在案的IDS(相比之下,年龄匹配的普通人群为2.9%)。在394289患者年的观察期内,3824例CHD患者死亡,31017例患者发生全因死亡或急诊入院的联合事件。多变量Cox比例风险分析显示,ISI的存在[风险比(HR):2.14,P<0.001]或记录在案的IDS(HR:1.77,P = 0.035)是全因死亡的独立预测因素。此外,在随访期间,ISI和确诊的IDS与急诊入院风险显著增加相关(竞争风险分析中两者P均为0.01)。
CHD患者中免疫能力有限很常见,且与发病和死亡风险增加相关。这凸显了进行结构化IDS筛查以及与免疫学专家合作的必要性,因为免疫缺陷可能适合特定治疗。此外,需要开展研究来评估IDS患者是否可能从强化抗生素防护或针对性预防中获益。